Respiratory medicine
-
Respiratory medicine · Nov 2013
Multicenter Study Observational StudyAssessment of asthma control: the SERENA study.
Several studies suggest that many asthmatic subjects have uncontrolled asthma. The control of asthma is now considered the major goal of therapy. ⋯ This study highlights the importance in clinical practice of a periodic assessment by a validated asthma control instrument and exacerbations/health care contacts during previous year. Clinicians should be aware that a significant proportion of patients can have uncontrolled asthma, despite regular pharmacological treatment.
-
Respiratory medicine · Nov 2013
Can exhaled nitric oxide differentiate causes of pulmonary fibrosis?
Interstitial lung diseases (ILD) comprise a heterogeneous group of disorders, and when diagnosed at the stage of pulmonary fibrosis, the underlying lung disease can sometimes be difficult to identify. The aim of the present study was to determine whether there are differences in FENO (fraction of exhaled nitric oxide) between different subtypes of fibrotic ILD. ⋯ FENO could be a tool for differentiating chronic HP from other types of pulmonary fibrosis. The mechanism involved seems to be bronchiolar disease.
-
Respiratory medicine · Nov 2013
Randomized Controlled Trial Multicenter StudyCost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler(®)+tiotropium (TIO) HandiHaler(®) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA). ⋯ BUD/FORM + TIO represents a clinical and economic benefit to health systems and society for the treatment of COPD in the Nordic countries. (ClinicalTrials.gov Identifier: NCT00496470).
-
Respiratory medicine · Nov 2013
Randomized Controlled Trial Multicenter StudyEfficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD.
To evaluate the efficacy and tolerability of the selective CRTh2 (DP2) receptor antagonist AZD1981 compared with placebo in patients with moderate to severe COPD. ⋯ There was no beneficial clinical effect of AZD1981, at a dose of 1000 mg twice daily for 4 weeks, in patients with moderate to severe COPD. AZD1981 was well tolerated and no safety concerns were identified.
-
Respiratory medicine · Nov 2013
Multicenter Study Controlled Clinical TrialFunctional and psychological variables both affect daily physical activity in COPD: a structural equations model.
Daily physical activity (DPA) level is reduced in patients with COPD. The aim of this study was to investigate the association of DPA with functional and psychological variables in these patients. ⋯ ClinicalTrials.gov, NCT00614796.